Dr. Jonathan C. Fox is a distinguished cardiovascular medicine specialist and executive leader with extensive expertise in drug development for rare cardiac conditions. He currently serves as President and Chief Medical Officer for cardiovascular and renal diseases at BridgeBio Pharma, a clinical-stage biotechnology company focused on genetically targeted therapies. Previously, Dr. Fox held the position of Chief Medical Officer at MyoKardia, where he played a pivotal role in the development of Camzyos® (mavacamten) for obstructive hypertrophic cardiomyopathy. His career spans over two decades in the pharmaceutical industry, including senior research and development positions at Merck Research Laboratories and AstraZeneca, complemented by academic appointments at the University of Pennsylvania School of Medicine.
Dr. Fox's groundbreaking contributions to cardiovascular therapeutics have significantly advanced treatment options for patients with rare and complex heart conditions. As one of the key developers of mavacamten at MyoKardia, he helped pioneer a novel approach to treating obstructive hypertrophic cardiomyopathy, a condition with limited therapeutic options prior to this innovation. His work has established new clinical development pathways for precision cardiovascular medicines targeting specific genetic and molecular mechanisms underlying cardiac disorders. Dr. Fox has been instrumental in advancing multiple cardiovascular drug candidates through clinical development, applying his dual expertise in cardiology and clinical trial design to transform scientific discoveries into meaningful therapeutic interventions.
Beyond his direct research contributions, Dr. Fox serves on the board of directors for Edgewise Therapeutics and as a trustee of the Lankenau Institute for Medical Research, where he provides strategic guidance on innovative therapeutic approaches for muscle disorders. He maintains an adjunct faculty position at the Stanford University Cardiovascular Institute, continuing to contribute to academic medicine and mentor the next generation of cardiovascular researchers. Dr. Fox's current work focuses on developing genetically targeted therapies that address the root causes of cardiovascular and renal diseases through precision medicine approaches. His leadership continues to shape the future of cardiovascular therapeutics with a commitment to translating scientific breakthroughs into treatments that fundamentally improve patients' lives.
